Differential effects of tyrosine kinase inhibitors on contraction and relaxation of the aortas of normotensive and hypertensive rats

European Journal of Pharmacology

Volumn 374, Issue 1, 1999, Pages 49-58

  Zerrouk, Abdellatif ^b   Auguet, Michel ^a   Dabiré, Hubert ^b   Brisac, Anne Marie ^b   Safar, Michel ^b   Chabrier, Pierre Etienne ^a  

^a Institut Henri Beaufour   (France)

^b INSERM   (France)

Author keywords

Cyclopiazonic acid; Endothelin 1; Endothelium; Noradrenaline; Spontaneously hypertensive rat (SHR); Tyrosine kinase

Indexed keywords

2,5 DIHYDROXYCINNAMIC ACID METHYL ESTER; CARBACHOL; CYCLOPIAZONIC ACID; ENDOTHELIN 1; ENDOTHELIUM DERIVED RELAXING FACTOR; GENISTEIN; NITRIC OXIDE; NORADRENALIN; PHENYLEPHRINE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; VANADATE SODIUM;

ANIMAL TISSUE; AORTA CONSTRICTION; ARTERY DILATATION; ARTICLE; CONTROLLED STUDY; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; CALCIUM; CARBACHOL; ENDOTHELIN-1; HYPERTENSION; INDOLES; MALE; PROTEIN-TYROSINE KINASES; PROTEIN-TYROSINE-PHOSPHATASE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; VASOCONSTRICTION; VASODILATION;

EID: 0033035643     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00304-0     Document Type: Article

References (43)

1. Abebe W., Agrawal D.K. Role of tyrosine kinases in noradrenaline-induced contraction of vascular smooth muscle. J. Cardiovasc. Pharmacol. 26:1995;153-159.
2. Akiyama T., Ishida J., Nakagawa S., Ogaware H., Watanabe S., Itoh N., Shibuy M. Genistein, a specific inhibitor of tyrosine-specific tyrosine kinases. J. Biol. Chem. 262:1987;5592-5595.
3. Auguet M., Delaflotte S., Pirotzky E., Clostre F., Braquet P. Role of endothelium on phenylephrine-triggered contractile events in aorta of spontaneously hypertensive rats. Fundam. Clin. Pharmacol. 3:1989;655-664.
4. Belmadani S., Mathieu E., Levy B.I., Boulanger C.M. Role of tyrosine kinases in regenerated endothelial cell dysfunction. Hypertension. 30:1997;992.
5. Bohr D.F., Webb R.C. Vascular smooth muscle membrane in hypertension. Annu. Rev. Pharmacol. Toxicol. 28:1988;389-409.
6. Cardillo M., Kilcoyne C.M., Quyyumi A.A., Cannon III R.O., Panza J.A. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension. Circulation. 97:1998;851-856.
7. Chopra L.C., Hucks D., Twort C.H., Ward J.P. Effects of protein tyrosine kinase inhibitors on contractility of isolated bronchioles of the rat. Am. J. Respir. Cell Mol. Biol. 16:1997;372-378.
8. Dolor R.J., Hurwitz L.M., Mizra Z., Strauss H.C., Whorton A.R. Regulation of extracellular calcium entry in endothelial cells: role of intracellular calcium pool. Am. J. Physiol. 262:1992;C171-C181.
9. Florian J.A., Watts S.W. Epidermal growth factor: a potent vasoconstrictor in experimental hypertension. Am. J. Physiol. 276:1999;H979-H983.
10. Folkow B. Physiological aspects of primary hypertension. Physiol. Rev. 62:1982;347-504.
11. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
12. 2 in the SHR aorta. Circ. Res. 76:1995;1003-1010.
13. 2+ entry for endothelial nitric oxide production. Jpn. J. Pharmacol. 67:1995;181-183.
14. Hollenberg M.D. Tyrosine kinase pathways and the regulation of smooth muscle contractility. Trends Pharmacol. Sci. 15:1994;108-114.
15. Hutcheson I.R., Griffith T.M. Central role of intracellular calcium stores in acute flow- and agonist-evoked endothelial nitric oxide release. Br. J. Pharmacol. 122:1997;117-125.
16. Jinsi A., Paradise J., Deth R.C. A tyrosine kinase regulates?-adrenoceptor-stimulated contraction and phospholipase D activation in the rat aorta. Eur. J. Biol. 302:1996;183-190.
17. Kam K.L., Hendriks M.C.G., Pijl A., Van Marle J., Van Veen H.A., Pfaffendorf M., Van Zwieten P.A. Contractile responses to various stimuli in isolated resistance vessels from spontaneously hypertensive and streptozocin-diabetic rats. J. Cardiovasc. Pharmacol. 27:1996;167-175.
18. Konishi M., Su C. Role of endothelium in dilator responses of spontaneously hypertensive rat arteries. Hypertension. 5:1983;881-886.
19. 2+ response to acetylcholine in endothelial cells from aorta of aldosterone-salt hypertensive rats. Am. J. Hypertens. 8:1995;404-408.
20. Malloy L.G., Sauro M.D. Tyrosine kinase inhibition suppresses angiotensin contraction in hypertensive and normotensive small resistance arteries. Life Sci. 58:1996;PL317-PL324.
21. Malloy C.J., Taylor D.S., Weber H. Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat aortic smooth muscle cells. J. Biol. Chem. 268:1993;7338-7345.
22. 2+. Pharmacol. Rev. 40:1988;87-119.
23. 2+ mobilization in intact endothelial cells of rabbit aorta. Arterioscler. Thromb. Vasc. Biol. 17:1997;1561-1567.
24. 2+-ATPase inhibitor, cyclopiazonic acid, possibly through nitric oxide formation. Br. J. Pharmacol. 111:1994;655-662.
25. Ohanian J., Ohanian V., Shaw L., Bruce C., Heagerty A.M. Involvement of tyrosine phosphorylation in endothelin-1-induced calcium-sensitization in rat small mesenteric arteries. Br. J. Pharmacol. 120:1997;653-661.
26. Panek R.L., Lu G.H., Klutchko S.R., Batley B.L., Dahring T.K., Hamby J.M., Hallak H., Doherty A.M., Keiser J.A. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther. 283:1997;1433-1444.
27. Panza A.J., Casino P.R., Kolcoyne C.M., Quyyumi A.A. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J. Am. Coll. Cardiol. 23:1994;1610-1616.
28. Raeymaekers L., Wuytack F., Eggermont J., De Schutter G., Casteels R. Isolation of plasma-membrane fraction from gastric smooth muscle. Biochem. J. 210:1983;315-322.
29. Saifeddine M., Laniyonu A., Yang S.G., Hollenberg M.D. Tyrosine kinase inhibitors and the contractile action of angiotensin II in vascular tissue. Pharmacol. Commun. 1:1992;177-184.
30. Sauro M.D., Sudakow R., Burns S. In vivo effects of angiotensin II on vascular smooth muscle contraction and blood pressure are mediated through a protein kinase dependent mechanism. J. Pharmacol. Exp. Ther. 277:1996;1744-1750.
31. Savineau J.P., Gonzalez De La Fuente P., Marthan R. Effects of modulators of tyrosine kinase activity on agonist-induced contraction in the rat pulmonary vascular smooth muscle. Pulm. Pharmacol. 9:1996;189-195.
32. 2+ influx pathway. Biochem. J. 284:1992;521-530.
33. Semenchuk L., Di Salvo J. Receptor-activated increases in intracellular calcium and protein tyrosine phosphorylation in vascular smooth muscle cells. FEBS Lett. 370:1995;127-130.
34. Shibata S., Kurahashi K., Kuchü M. A possible etiology of contractility impairment of vascular smooth muscle from spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 185:1973;406-417.
35. Sim M.K., Singh M. Decreased responsiveness of the aortae of hypertensive rats to acetylcholine, histamine and noradrenaline. Br. J. Pharmacol. 10:1987;147-150.
36. Spector S., Fleish J.H., Maling H.M., Brodie B.B. Vascular smooth muscle reactivity in normotensive and hypertensive rats. Science. 166:1969;1300-1310.
37. Swarup G., Cohen S., Garbers D.L. Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem. Biophys. Res. Commun. 107:1982;1104-1109.
38. Wang R., Sauvé R., de Champlain J. Abnormal regulation of cytosolic free calcium in vascular endothelial cells from spontaneously hypertensive rats. J. Hypertension. 13:1995;993-1001.
39. Watts W.S., Yeum C.H., Campbell G., Webb R.C. Serotonin stimulates protein tyrosyl phosphorylation and vascular contraction via tyrosine kinase. J. Vasc. Res. 33:1996;288-298.
40. Yang S.-G., Saifeddine M., Laniyonu A., Hollenberg M.D. Distinct signal transduction pathways for angiotensin-II in guinea pig gastric smooth muscle: differential blockade by indomethacin and tyrosine kinase inhibitors. J. Pharmacol. Exp. Ther. 264:1993;958-966.
41. Zerrouk A., Auguet M., Chabrier P.E. Augmented endothelium-dependent contraction to angiotensin II in the SHR aorta: role of an inducible cyclooxygenase metabolite. J. Cardiovasc. Pharmacol. 31:1998;525-533.
42. 2+ influx through non-specific cation channels in endothelial cells. Eur. J. Pharmacol. 251:1994;119-125.
43. 2+ in EDRF release in rat aorta. J. Vasc. Res. 31:1994;18-24.